Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali.
用于联合芳香酶抑制剂或氟维司群治疗激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性的晚期或转移性乳腺癌成人患者。
The Angeles Clinic and Research Institute, Los Angeles, California, United States
Florida Cancer Specialists, Fort Myers, Florida, United States
H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Inova Schar Cancer Institute, Fairfax, Virginia, United States
M D Anderson Cancer Center, Houston, Texas, United States
National Taiwan University Hospital, Taipei, Taiwan
Institut Bergonié, Bordeaux, France
Centre Léon Bérard, Lyon, France
Institut Paoli Calmettes, Marseille, France
Massachusetts General Hospital, Boston, Massachusetts, United States
Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain
UZ Gasthuisberg Leuven, Leuven, Belgium
Hospital of Prato, Prato, Please select:, Italy
Grand Hôpital de Charleroi, Charleroi, Belgium
Jessa Ziekenhuis, Hasselt, Belgium
Brustzentrum Basel - Praxis für ambulante Tumortherapie, Basel, Switzerland
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.